Services
- Custom AAV Production
- AAV Vector System
- Custom Adenovirus Production
- Custom Lentivirus Production
- Pre-made AAV Production
- Pre-made Adenovirus Production
- Pre-made Lentivirus Production
- AAV-LC3 Autophagy Flux Detection
- Ad-LC3 Autophagy Flux Detection
- Lv-LC3 Autophagy Flux Detection
- AAV Control Virus Production
- CRISPR/Cas9 AAV Production
- CRISPR/Cas9 Adenovirus Production
Products
Supports
SOCAIL MEDIA
AAV2.7m8 variant Rep-Cap plasmid (inner ear&retina-validated serotype AAV-RC plasmid)
AAV protocol Download
AAV User Manual Download
Capsid mutant-AAV serotype 2 variant (AAV2.7m8) system-Introduction
GeneMedi's AAV2.7m8 variant Rep-Cap plasmid (iner ear&retina-validated serotype AAV-RC plasmid), also named AAV2.7m8 variant-RC plasmid, is part of AAV2.7m8 variant packaging system. AAV2.7m8 variant Rep-Cap plamid supplies the AAV2 Rep(replication) proteins and the AAV2.7m8 variant capsid protein.
You can produce AAV2.7m8 variant paticle in 293T cell line in high titer using GeneMedi's AAV2.7m8 variant Rep-Cap plasmid with GeneMedi's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV2.7m8 vector has been validated in inner ear. AAV2.7m8 infects both inner hair cells (IHCs) and outer hair cells (OHCs) with high efficiency. In addition, AAV2.7m8 infects inner pillar cells and inner phalangeal cells with high efficiency, with potential applications in tissue-specific gene therapy.AAV2-7m8 also shows the potential tropism in retina in vivo and retinal cell in vitro.
| Product Name | Contents | Price(In USD) | Qty | Sum(In USD) |
|---|---|---|---|---|
| AAV2 variant (AAV2.7m8) Rep-Cap plasmid | Serotype: AAV2 variant (AAV2.7m8) Size: 5ug |
935 | ||
| Shipping Cost: | 120.00 | |||
| Total: | ||||
AAV2 capsid variant (AAV2.7m8) tissue tropism and gene transduction (serotype-specific AAV infection)
The tissue tropism of AAV2.7m8 vector has been validated in inner ear. AAV2.7m8 infects both inner hair cells (IHCs) and outer hair cells (OHCs) with high efficiency. In addition, AAV2.7m8 infects inner pillar cells and inner phalangeal cells with high efficiency, with potential applications in tissue-specific gene therapy.
.jpg)
Virus and titer: AAV2 variant (AAV2.7m8) vector system, 1×1012 vg/ml Animal: mouse, C57, 2 months Infection site: retina Gene delivery method: subretinal cavity injection, 3μl Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy
Other AAV Rep-Cap Plasmid
